Stay updated on Daratumumab Combo Salvage Therapy in MM Clinical Trial

Sign up to get notified when there's something new on the Daratumumab Combo Salvage Therapy in MM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab Combo Salvage Therapy in MM Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:45:14.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in a Phase II study.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:27.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    41%
    Check dated 2024-05-22T21:16:52.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update or modification in the estimated completion date of the medical study related to Multiple Myeloma and the combination therapy being investigated.
    Difference
    0.1%
    Check dated 2024-05-03T08:33:49.000Z thumbnail image
  9. Check
    45 days ago
    Change Detected
    Summary
    The value -10 2024 2024 01 08 -10 01 has recently changed to 05- 2025 2025 04 29 (Estimated) 05- 04. This change likely reflects an update in the estimated study completion date for the clinical trial involving Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma, indicating a potential shift in the timeline for the research.
    Difference
    0.8%
    Check dated 2024-05-02T03:47:10.000Z thumbnail image
  10. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:53:00.000Z thumbnail image

Stay in the know with updates to Daratumumab Combo Salvage Therapy in MM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo Salvage Therapy in MM Clinical Trial page.